Crohn's News

FDA Approves Tysabri reg; For The Treatment Of Moderate-To-Severe Crohn's Disease

Mon, 23 Jun 2008 14:40:12 GMT

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced the approval of a supplemental Biologics License Application (sBLA) by the U.

Full text

Improved Treatment For Crohn's Disease

Mon, 23 Jun 2008 14:40:11 GMT

An international research study, published in The Lancet, has thrown into question the current method of treating Crohn's disease - opening the door to a safer and more effective treatment option for sufferers of the chronic disease.

Full text

Asacol 800mg MR Tablets Dosed At 4.8g Day Herald Fast Symptom Relief And Improved Quality Of Life For Moderately Active UC Patients

Mon, 23 Jun 2008 14:40:11 GMT

Procter & Gamble Pharmaceuticals (NYSE: P&G) announced that Asacol(R) (mesalazine) 800mg Modified Release (MR) tablets are now available in the UK for the treatment of mild to moderate acute exacerbations of ulcerative colitis (UC), and the maintenance of remission in UC and Crohn's ileo-colitis patients.

Full text

Inflammatory Bowel Disease May Mimic Gynecological Disorders In Its Clinical Presentation

Mon, 23 Jun 2008 14:40:10 GMT

Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract.

Full text

New Treatment Strategy For Crohn's Disease Shows Promise

Mon, 23 Jun 2008 14:40:09 GMT

When treating patients with Crohn's disease, early use of an intensivecombined immunosuppression (CI) in combination withconventional management is more effective than the current standard, treatment with corticosteroids.

Full text

Early Data On Cimzia reg; Shows Promise In Crohn's Patients Without Infliximab

Mon, 23 Jun 2008 14:40:09 GMT

Datafrom the WELCOME trial presented at the third congress of the EuropeanCrohn's and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia (certolizumab pegol) is effective in Crohn's patientsshowing intolerance or no response to infliximab.

Full text

Hope For Crohn's Patients With Fistulas Found In HUMIRA Adalimumab

Mon, 23 Jun 2008 14:40:08 GMT

At the recent European Crohn's and Colitis Organization (ECCO) annualmeeting in Lyon, France, Abbott Laboratories announced that HUMIRA(Adalimumab) is successful in the treatment of fistulas in susceptibleCrohn's patients.

Full text

Caspase-12: MUHC Researcher Finds New Defense Mechanism Against Intestinal Inflammation

Mon, 23 Jun 2008 14:40:07 GMT

The body's first line of defence against pathogenic bacteria that we ingest may not be the immune system but rather the cells that line the intestine.

Full text

Food For Life Baking Co., Inc. Recalls Spelt Bread , California - Product Contains Undeclared Wheat

Mon, 23 Jun 2008 14:40:06 GMT

Food For Life Baking Company of Corona, California is voluntarily recalling 2, 241 cases of Spelt Bread (UPC# 07347200168) because they contain spelt grain which is known to be a hybrid of wheat.

Full text

CHMP Upholds Negative Opinion For The EU Application For Cimzia R In The Treatment Of Crohn's Disease

Mon, 23 Jun 2008 14:40:05 GMT

UCB announced that the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) has rejected the appeal following CHMP refusal of the Marketing Authorization Application (MAA) for Cimzia (certolizumab pegol) in the treatment of patients with Crohn's disease, a chronic and debilitating inflammatory disease.

Full text